An Oral, Selective Tyrosine Kinase 2 Inhibitor, BMS-986165, Reduced Absolute Psoriasis Area and Severity Index in a Phase 2 Trial in Psoriasis. J of Skin [Internet]. 2020 Sep. 2 [cited 2025 Apr. 19];4(5):s27. Available from: https://skin.dermsquared.com/skin/article/view/976